•
AN
ANRO
Alto Neuroscience Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
546.46M
Volume
8.64K
52W High
$20.91
52W Low
$1.60
Open
$0.00
Prev Close
$17.57
Day Range
0.00 - 0.00
About Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Latest News
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire Inc.•Oct 7
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
GlobeNewswire Inc.•Sep 19
ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
GlobeNewswire Inc.•Sep 19
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire Inc.•Sep 18
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
GlobeNewswire Inc.•Sep 18
ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
GlobeNewswire Inc.•Sep 16
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire Inc.•Sep 14
ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
GlobeNewswire Inc.•Sep 12